Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction

References

1. Adachi A., Gendelman H. E., Koenig S., Folks T., Willey R., Rabson A., Martin M. A. 1986; Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology 59: 284–291
   [Google Scholar]
2. Arthur L. O., Bess J. W.Jr Sowder R. C.II Benveniste R. E., Mann D. L., Chermann J. -C., Henderson L. E. 1992; Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:1935–1938
   [Google Scholar]
3. Franke E. K., Yuan H. E. H., Luban J. 1994; Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359–362
   [Google Scholar]
4. Fujita T., Inoue T., Ogawa K., Iida K., Tamura N. 1987; The mechanism of action of decay-accelerating factor (DAF) : DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. Journal of Experimental Medicine 166:1221–1228
   [Google Scholar]
5. Gomez M. B., Hildreth J. E. K. 1995; Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1. Journal of Virology 69: 4628–4632
   [Google Scholar]
6. Kojima A., Iwata K., Seya T., Matsumoto M., Ariga H., Atkinson J. P., Nagasawa S. 1993; Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3- fragment deposition and cytolysis. Journal of Immunology 151:1519–1527
   [Google Scholar]
7. Liszewski M. K., Atkinson J. P. 1992; Membrane cofactor protein. Current Topics in Microbiology and Immunology 4:8–13
   [Google Scholar]
8. Lublin D. M., Coyne K. E. 1991; Phospholipid -anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement- mediated cell damage. Journal of Experimental Medicine 174:35–44
   [Google Scholar]
9. Lublin D. M., Liszewski M. K., Post T. W., Arce M. A., Le Beau M. M., Rebentisch M. B., Lemons R. S., Seya T., Atkinson J. P. 1988; Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP) : evidence for inclusion in the multigene family of complement-regulatory proteins. Journal of Experimental Medicine 168:181–194
   [Google Scholar]
10. Marschang P., Sodroski J., Wurzner R., Dierich M. P. 1995; Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 inactivation by human complement. European Journal of Immunology 25:285–290
    [Google Scholar]
11. Medof M. E., Lublin D. M., Holers V. M., Ayers D. J., Getty R. R., Leykam J. F., Atkinson J. P., Tykocinski M. L. 1987; Cloning and characterization of cDNAs encoding the complete sequence of decay accelerating factor of human complement. Proceedings of the National Academy of Sciences USA: 842007–2011
    [Google Scholar]
12. Meri S. 1994; Protectin (CD59): complement lysis inhibitor and prototype domain in a new protein superfamily. Immunologist 2:149–155
    [Google Scholar]
13. Montefiori D. C., Cornell R. J., Zhou J. Y., Zhou J. T., Hirsch V. M., Johnson P. R. 1994; Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immuno-deficiency viruses and possible targets for vaccine protection. Virology 205:82–92
    [Google Scholar]
14. Orentas R. J., Hildreth J. E. K. 1993; Association ofhost cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Research and Human Retroviruses 9: 1157–1165
    [Google Scholar]
15. Palker T. J., Clark M. E., Langlois A. J., Matthews T. J., Weinhold K. J., Randall R. R., Bolognesi D. P., Haynes B. F. 1988; Type- specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proceedings of the National Academy of Sciences USA: 85 1932–1936
    [Google Scholar]
16. Rollins S. A., Sims P. J. 1990; The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. Journal of Immunology 144:3478–3483
    [Google Scholar]
17. Saifuddin M., Parker C. J., Peeples M. E., Gorny M. K., Zolla-Pazner S., Ghassemi M., Rooney I. A., Atkinson J. P., Spear G. T. 1995; Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. Journal of Experimental Medicine 182:501–509
    [Google Scholar]
18. Seya T., Ballard L. N., Bora N., Cui W., Kumar B. V., Atkinson J. P. 1988; Distribution of membrane cofactor protein (MCP) of complement on human peripheral blood cells. European Journal of Immunology 18:1289–1294
    [Google Scholar]
19. Sullivan B. L., Knopoff E. J., Saifuddin M., Takefman D. M., Saarloos M. -N., Sha B. E., Spear G. T. 1996; Susceptibility virus to complement-mediated lysis: evidence for a role in clearance of virus in vivo. Journal of Immunology 157:1791–1798
    [Google Scholar]
20. Terstappen L. W. M., Nguyen M., Lazarus H. M., Medof M. E. 1992; Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. Journal of Leukocyte Biology 52:652–660
    [Google Scholar]
21. Zhao J., Rollins S. A., Maher S. E., Bothwell A. L. M., Sims P. J. 1991; Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. Journal of Biological Chemistry 266:13418–13422
    [Google Scholar]